Evotec’s new Washington site is ready to roll, and the U.S. has already called first dibs for COVID-19 antibody supplies

After announcing its new location in Redmond, Washington last week, Evotec says their first order of business in the new 130,000-square-foot campus is to develop COVID-19 antibody drugs.

Just – Evotec Biologics, the company’s subsidiary, holds a facility in Seattle which to date employs over 250 people with the expectation of growing to more than 300 hires by 2022.

READ THE STORY at FiercePharma »